NeoGenomics Gains Medicare Coverage for RaDaR ST Monitoring
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
Austin, Texas – August 27, 2026 Natera and Angiex have entered a new collaboration to assess treatment response to...
LEXINGTON, Mass., Aug. 26, 2026 Agenus Inc. announced updated results from the peer-reviewed Phase 2 NEST trial, providing longer...
AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
LOS ANGELES, July 21, 2026 City of Hope has launched the national Phase 2 IMMUNO-BIOMAP clinical trial to better...
KUALA LUMPUR, Malaysia, July 21, 2026 Haier Biomedical showcased its next-generation Digital Blood Management Platform at the ISBT Congress...
CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...
SECAUCUS, N.J., June 24, 2026 Quest Diagnostics announced that the New York State Department of Health’s Clinical Laboratory Evaluation...
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
